



# Secundum Artem

*Current & Practical Compounding  
Information for the Pharmacist.*

## COMPOUNDING OPHTHALMIC LIQUIDS

### INTRODUCTION

Ophthalmic solutions are sterile, free from foreign particles and especially prepared for instillation into the eye. Ophthalmic suspensions are sterile liquid preparations that contain solid particles in a suitable vehicle intended for instillation into the eye.

### COMPOSITION(S)

In addition to the active drugs, ophthalmic preparations contain a number of excipients, including vehicles, buffers, preservatives, tonicity adjusting agents, antioxidants and viscosity enhancers. Important in the formulation process is the use of ingredients that are nonirritating and compatible with the eyes.

### PREPARATION METHODS/TECHNIQUES

All work must be done in a clean-air environment, such as a laminar flow hood, by qualified aseptic compounding pharmacists. The source of all the ingredients must be the highest grade that can be reasonably obtained.

#### Solutions:

1. Accurately weigh/measure each of the ingredients.
2. Dissolve the ingredients in about 3/4 of the quantity of Sterile Water for Injection and mix well.
3. Add sufficient Sterile Water for Injection to volume and mix well.
4. Determine the pH, clarity and other quality control factors from a sample of the solution.
5. Filter through a sterile 0.2 micron filter into a sterile ophthalmic container.
6. Package and label.
7. If a large number are to be prepared, select a

random sample to be checked for sterility and to be assayed.

#### Suspensions:

1. Accurately weigh/measure each of the ingredients.
2. Mix the ingredients in about 3/4 of the quantity of Sterile Water for Injection and mix well.
3. Add sufficient Sterile Water for Injection to volume and mix well.
4. Determine the pH, and other quality control factors from a sample of the suspension
5. Package in a suitable container for autoclaving.
6. Autoclave, cool and label.
7. If a large number are to be prepared, select a random sample to be checked for sterility and to be assayed.

#### Or

1. Accurately weigh/measure each of the ingredients.
2. Sterilize each of the ingredients by a suitable method.
3. Mix the ingredients in about 3/4 of the quantity of Sterile Water for Injection and mix well.
4. Add sufficient Sterile Water for Injection to volume and mix well.
5. Determine the pH, and other quality control factors from a sample of the suspension
6. Package and label.
7. If a large number are to be prepared, select a random sample to be checked for sterility and to be assayed.

### PHYSICOCHEMICAL UNIQUENESS OF COMMON INGREDIENTS

Considerations in preparing ophthalmic solutions involve clarity, tonicity, pH/buffers, sterility, preservatives, antioxidants, viscosity enhancers, and proper packaging.

*Considerations in preparing ophthalmic solutions involve clarity, tonicity, pH/buffers, sterility, preservatives, antioxidants, viscosity enhancers, and proper packaging.*

*Beyond-use recommendations can be extended if there is supporting scientific stability information as described in the USP23/NF18.*

**Clarity**-Ophthalmic solutions must be free from foreign particles, which is generally accomplished by filtration. The filtration process also helps to achieve clarity of the solution. Table 1 contains a list of usable clarifying agents.

**Tonicity**-Lacrimal fluid has an isotonicity value equivalent to that of a 0.9% sodium chloride solution. However, the eye can tolerate a value as low as 0.6% and as high as 1.8% sodium chloride equivalency. Some ophthalmic solutions will be hypertonic by nature of the high concentration required of the drug substance. Others will be hypotonic and will require the addition of a substance to attain the proper tonicity range. Sodium chloride, boric acid and dextrose are commonly used. Three hundred mOsm/L is ideal with 200-600 mOsm/L acceptable.

**pH and Buffering**-Ophthalmic solutions are ordinarily buffered at the pH of maximum stability for the drug(s) they contain. The buffers are included to minimize any change in pH during the storage life of the drug; this can result from absorbed CO<sub>2</sub> from the air or from hydroxyl ions from a glass container. Changes in pH can affect the solubility and the stability of drugs, consequently, it is important to minimize fluctuations in pH. The buffer system should be designed sufficient to maintain the pH throughout the expected shelf-life of the product but with a low buffer capacity so as soon as the ophthalmic solution is dropped into the eye, the buffer system of the tears will rapidly bring the pH of the solution back to that of the tears. This is accomplished by using as low a concentration of the buffers salts as possible but still be effective. Generally a buffer capacity less than 0.05 is desired. pH generally in the range of 4-8 is considered optimum.

**Sterility**-Ophthalmic solutions must be sterile. Sterility is best achieved through sterile filtration using a sterile membrane filter of 0.45 or 0.2 micron pore size and filtering into a sterile container. Other methods of sterilizing ingredients or components of ophthalmics that can be used by compounding pharmacists include dry heat, steam under pressure (autoclaving) and gas sterilization (ethylene oxide).

**Preservation**-Since most ophthalmic solutions/suspensions are prepared in multiple use containers, they must be preserved. The selected preservative must be compatible with the active drug as well as all the other excipients in the product. Common preservatives for ophthalmic products are shown in Table 2.

**Antioxidants** may be required for selected active drug ingredients. Tables 3 contains antioxidants that can be used in ophthalmic preparations.

**Viscosity enhancers**-An increase in the viscosity of ophthalmic products will result in a longer residence time in the eye, providing a longer time for drug absorption and effect. Numerous materials are used, among which methylcellulose is the most common, generally in a concentration of about 0.25% if the 4000 cps grade is used. If methylcellulose is autoclaved, it will come out of solution. However, it can be redispersed after cooling, especially if placed in a refrigerator. Hydroxypropyl methylcellulose in the range of 0.5 to 1% is a good viscosity enhancer, while polyvinyl alcohol 0.5 to 1.5% w/v is an alternative. Solution viscosity in the range of 25-50 cps is common. It is important that solution clarity be maintained with the use of these viscosity enhancers. Suitable viscosity increasing addi-

tives are shown in Table 4.

**Packaging** of ophthalmic solutions is appropriately done in sterile dropper bottles or individual doses can be placed in sterile syringes, without needles.

Ophthalmic suspension particles must be of such a size that they do not irritate and/or scratch the cornea, therefore a micronized form of the drug is required. Ophthalmic suspensions must also be free from agglomeration or caking.

## INCOMPATIBILITIES

Zinc salts can form insoluble hydroxides at a pH above 6.4, so a Boric Acid Solution vehicle may be selected. It also has a lower pH (about pH 5) and slight buffering action.

Nitrates or salicylates are incompatible with solutions of benzalkonium Chloride, therefore it should be replaced with 0.002% phenylmercuric nitrate.

Sodium chloride cannot be used to adjust the tonicity of silver nitrate solutions since silver chloride would precipitate. Sodium nitrate should be used to adjust the tonicity and phenylmercuric nitrate can be used as the preservative in this situation.

## STORAGE/LABELING

Generally, ophthalmic preparations should be stored at either room or refrigerated temperatures and should not be frozen.

## STABILITY

Beyond-use dates for water-containing formulations is not later than 14 days, when stored at refrigerated temperatures, for products prepared from ingredients in solid form. If nonaqueous liquids, the beyond-use recommendation is not later than 25% of the time remaining until the products expiration date or 6 months, whichever is earlier. For all others, the recommended beyond-use recommendation is the intended duration of therapy or 30 days, whichever is earlier. These beyond-use recommendations can be extended if there is supporting valid scientific stability information, as explained in the General Compounding Chapter of the United States Pharmacopeia 23/National Formulary 18.

## EXAMPLE VEHICLES

### Isotonic Sodium Chloride Solution

Sodium Chloride USP		0.9 g
Benzalkonium Chloride		1:10,000
Sterile Water for Injection	qs	100 mL

### Boric Acid Solution

Boric Acid USP		1.9 g
Benzalkonium Chloride		1:10,000
Sterile Water for Injection	qs	100 mL

### Rx Artificial Tears

Polyvinyl alcohol	1.5%
Povidone	0.5%
Chlorobutanol	0.5%
0.9% Sodium chloride solution	qs

1. Calculate the quantity of each ingredient for the total amount to be prepared.
2. Accurately weigh or measure each ingredient.

3. Dissolve all ingredients in the sterile 0.9% sodium chloride solution.
4. Filter through a 0.2 micron filter into a sterile ophthalmic container.
5. Package and label.

Agent	Usual Concentration (%)
Polysorbate 20	1%
Polysorbate 80	1%

**Table 2:** Common preservatives used in ophthalmic products.

Preservative Name	Usual Conc.	Conc. Range	Max. Conc. %	Incompatibilities
Chlorobutanol		0.5		
Quaternary Ammonium Compounds:	0.01%	0.004 - 0.02%		Soaps, anionic materials, salicylates, nitrates
Benzalkonium chloride			0.013	
Benzethonium chloride			0.01	
Organic Mercurials:		0.001-0.01%		Certain halides with phenylmercuric acetate.
Phenylmercuric acetate			0.004	
Phenylmercuric nitrate			0.004	
Thimerosal			0.01	
Parahydroxybenzoates			0.1%	Adsorption by macromolecules.

The maximum levels are listed by the FDA Advisory Review Panel on OTC Ophthalmic Drug Products (1979) for direct contact with the eye tissues and not for ocular devices such as contact lens products.

**Table 4:** Viscosity increasing agents for ophthalmic preparations.

**Table 3:** Antioxidants used for ophthalmic preparations.

Antioxidant	Usual Concentration (%)
Ethylenediaminetetraacetic acid	0.1%
Sodium bisulfite	0.1%
Sodium metabisulfite	0.1%
Thiourea	0.1%

Agent	Usual Concentration (%)
Hydroxyethylcellulose	0.8
Hydroxypropyl methylcellulose	1.0%
Methylcellulose	2.0%
Polyvinyl alcohol	1.4%
Polyvinylpyrrolidone	1.7%

**Table 1:** Wetting/clarifying agents used for ophthalmic preparations.



## The Paddock Solid-to-Liquid Solution

The physical and chemical properties of Ora-Plus® and Ora-Sweet® help ensure the stability of compounded oral liquids.

Over 40 formulations have been independently tested.

Call 1-800-328-5113 to receive copies of the studies or visit our website, [www.paddocklabs.com](http://www.paddocklabs.com).

## Secundum Artem on the Internet!

For up-to-date compounding formulas, product information  
and a complete listing of Secundum Artem articles,  
visit Paddock Laboratories' website:  
[www.paddocklabs.com](http://www.paddocklabs.com)

## WIN A FREE MORTAR & PESTLE!

Send in a  
completed  
BRC today!



**CONGRATULATIONS** to Joe Lawson, R.Ph. Beaufort, SC – winner of the recent Mortar & Pestle drawing.

YES, I would like to enter the current Secundum Artem Mortar & Pestle Drawing.

1. How many prescriptions do you compound per month? \_\_\_\_\_

2. What powders do you use in your compounding?

\_\_\_\_\_ Hydrocortisone \_\_\_\_\_ Nystatin

\_\_\_\_\_ Progesterone \_\_\_\_\_ Other \_\_\_\_\_

Name \_\_\_\_\_

Pharmacy Name \_\_\_\_\_

Pharmacy Address \_\_\_\_\_

City, State, Zip \_\_\_\_\_

Phone \_\_\_\_\_

**BUSINESS REPLY MAIL**


FIRST-CLASS MAIL PERMIT NO. 6837 MINNEAPOLIS MN

Postage will be paid by addressee



3940 Quebec Ave N  
Minneapolis MN 55427

NO POSTAGE  
NECESSARY  
IF MAILED  
IN THE  
UNITED STATES



## BIBLIOGRAPHY AND SUGGESTED READINGS

1. U.S. Pharmacopeia 23/National Formulary 18, Rockville MD, U.S. Pharmacopeial Convention, Inc., 1995.
2. Ansel HC, Popovich NG, Allen Jr LV. Pharmaceutical Dosage Forms and Drug Delivery Systems, Baltimore MD, Williams & Wilkins, 1995.
3. Gennaro AR., Remingtons: The Science and Practice of Pharmacy, Easton PA, Mack Publishing Co., 1995.
4. Wade A, Weller PJ. Handbook of Pharmaceutical Excipients, 2nd Ed, Washington DC, American Pharmaceutical Association, 1994.
5. Reynolds LA, Closson RG, Extemporaneous Ophthalmic Preparations, Vancouver WA, Applied Therapeutics, Inc., 1993.
6. Anon. Ophthalmic Drug Facts 1998. St Louis MO, Facts and Comparisons-A Wolters Kluwer Company, 1998.
7. Baner GS, Rhodes CT. Modern Pharmaceutics, 3rd Ed., New York, Marcel Dekker, Inc., 1995.
8. Ranade VV, Hollinger MA. Drug Delivery Systems. Boca Raton, CRC Press, 1996.



3940 Quebec Ave. N.  
Minneapolis, MN 55427-9841

Bulk Rate U.S. Postage PAID Minneapolis, MN Permit No. 1700
---